表紙
市場調査レポート

PharmaPoint:多発性硬化症 - 世界における医薬品の予測と市場分析

PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024

発行 GlobalData 商品コード 296450
出版日 ページ情報 英文 367 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
PharmaPoint:多発性硬化症 - 世界における医薬品の予測と市場分析 PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
出版日: 2015年09月10日 ページ情報: 英文 367 Pages
概要

多発性硬化症(MS)は慢性の炎症性神経疾患で、病理学的特徴は、中枢神経系の脱髄、軸索離断、神経変性です。根治的療法は依然として難しく、現在の疾患管理は、病態修飾療法(DMT)による生涯にわたる薬物療法に依存しています。

当レポートでは、世界におけるMS治療薬市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
    • MSの分類
  • 症状
    • 予後
    • QOL

第4章 疫学

  • 危険因子
    • MS患者の家族がMSを発症するリスクは1〜5%
    • 女性はMSを発症するリスクが2倍だが、男性は予後が悪い
    • 白人は他の人種/民族よりMSのリスクが高い
    • ビタミンDの予防効果は、出生地の緯度と月に関連
    • 環境暴露のタイミングがMSのリスクに影響を与える
    • 受動喫煙がMSのリスクを高め、予後を悪化させる
  • 併存疾患
    • 自己免疫疾患はMSの併存疾患
    • 精神疾患はMS患者の60%までに見られ、再発率に影響を与える
  • 世界の動向
    • 北米
    • 欧州
    • アジア
  • 予測手法
    • 利用した情報源
    • 予測の前提条件と手法
    • 利用しなかった情報源
  • 疫学予測
    • 有病者数
    • 有病者数:年齢別
    • 有病者数:性別
    • 発症件数
    • 発症件数:年齢別
    • 発症件数:性別
    • MSの亜形(サブタイプ)
  • 議論
    • 疫学的傾向に関する考察
    • 分析の限界
    • 分析の強み

第5章 疾患の管理

  • 診断
  • 治療の概要
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • カナダ
  • 中国
  • インド

第6章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル - 主要ブランド
    • Betaseron/Betaferon
    • Avonex
    • Rebif
    • Copaxone
    • Tysabri
    • Gilenya/Imusera
    • Aubagio
    • その他のDMT

第7章 機会とアンメットニーズ

  • 概要
  • アンメットニーズ
  • アンメットニーズのギャップ分析
  • 機会

第8章 パイプライン評価

  • 概要
  • 臨床試験マッピング
  • 臨床試験:フェーズ・段階別
  • 臨床開発中の有望な薬剤

第9章 現在/将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Biogen Idec
    • Teva Pharmaceutical Industries
    • Merck Serono (EMD Serono)
    • Sanofi
    • Bayer HealthCare Pharmaceuticals
    • Novartis International
    • Hoffmann-La Roche
    • GlaxoSmithKline

第10章 市場の見通し

  • 世界市場
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • カナダ
  • 中国
  • インド

第11章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC89PIDR

Multiple Sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system which leads to neurological disability. The exact underlying cause of the disease is poorly understood; however, it appears to involve a complex combination of genetic susceptibility and a non-genetic trigger. The MS therapeutics market has entered an exciting phase, with an upsurge of available treatment options. Over the forecast period, patients are expected to continue to switch to the oral disease-modifying therapies (DMTs), lessening the stronghold of the established injectable treatments. There are also several promising products in the late-stage pipeline, with a diverse range of mechanisms offering clinical advantages intended to address unmet needs. Both pipeline and marketed DMTs are seeking approval for the treatment of progressive MS, which currently represents a significant unmet need. These factors are expected to increase treatment rates throughout the 10MM resulting, driving market growth. However, this will be largely offset by brand erosion due to the emergence of biosimilars and generic small molecules.

Highlights

Key Questions Answered

  • The MS market has experienced a paradigm shift with the launch of first-line oral DMTs and efficacious escalation therapies. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
  • The current late-stage MS pipeline is robust and diverse, with 13 products in Phase III. GlobalData has profiled nine DMT drug therapies, of which eight are anticipated to launch during the forecast period. What impact will these drugs have on the market? How will they affect the treatment algorithm for MS? Will these drugs fulfil any of the unmet needs for MS?
  • The diagnosis and management of MS is challenging, even for the most experienced neurologists. How does the diagnosis and management of MS differ amongst the 10MM? Which DMT treatments are most commonly prescribed in each market, and how will prescribing patterns change over the forecast period?

Key Findings

  • The main driver of growth in the MS market will be the introduction of novel DMT products over the forecast period. Drugs targeting clinical unmet needs; such as improved efficacy, more convenient administration, or progressive MS approval; will increase treatment rates and drive market growth.
  • There is a high disparity between treatments for RRMS and progressive MS amongst the currently available drugs and, despite its diversity, the late late-stage pipeline remains skewed towards RRMS. As such, the RRMS market will become increasingly competitive making it more difficult for new entrants to gain patient share.
  • The biggest barrier for growth in the MS market will be competition from generic/biosimilar products for key branded therapies. In particular, the launch of generic small-molecules will hamper future growth of the MS market.
  • Considerable opportunity remains for products that meet the unmet needs in the MS market. A drug that prevents disease progression and the accumulation of disability would be viewed favourably. Additionally, targeting progressive MS will be an ongoing opportunity.

Scope

  • Overview of MS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized MS market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the MS therapeutics market.
  • Pipeline analysis: focus on nine late-stage pipeline MS drugs, discussing emerging trends as well as an overview of earlier phase drugs and a top-line analysis of therapeutic vaccines.
  • Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global MS therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MS therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global MS therapeutics market from 2014-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
    • 3.2.1. Relapse-Remitting Multiple Sclerosis
    • 3.2.2. Secondary Progressive Multiple Sclerosis
    • 3.2.3. Primary Progressive Multiple Sclerosis
    • 3.2.4. Progressive Relapsing Multiple Sclerosis
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. Family members of MS patients have a 1-5% risk of developing MS
    • 4.2.2. Women are twice as likely to develop MS, but men have a worse prognosis
    • 4.2.3. Caucasians have a higher risk of MS than any other race/ethnicity
    • 4.2.4. Protective effect of vitamin D on MS may relate to latitude and month of birth
    • 4.2.5. Timing of environmental exposures affects MS risk
    • 4.2.6. Exposure to smoking may increase MS risk and worsen prognosis
    • 4.2.7. Autoimmune Disease Comorbidities of MS
    • 4.2.8. Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates
  • 4.3. Global Trends
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast of Multiple Sclerosis (2014-2024)
    • 4.5.1. Diagnosed Prevalent Cases of MS
    • 4.5.2. Age-Specific Diagnosed Prevalent Cases of MS
    • 4.5.3. Sex-Specific Diagnosed Prevalent Cases of MS
    • 4.5.4. Diagnosed Incident Cases of MS
    • 4.5.5. Age-Specific Diagnosed Incident Cases of MS
    • 4.5.6. Sex-Specific Diagnosed Incident Cases of MS
    • 4.5.7. MS Subtypes
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis
  • 5.2. Treatment Overview
    • 5.2.1. Management of Acute Relapse
    • 5.2.2. Treatment with Disease-Modifying Therapies
    • 5.2.3. Symptomatic Therapies
  • 5.3. US
    • 5.3.1. Diagnosis
    • 5.3.2. Drug Treatment
  • 5.4. France
    • 5.4.1. Diagnosis
    • 5.4.2. Drug Treatment
  • 5.5. Germany
    • 5.5.1. Diagnosis
    • 5.5.2. Drug Treatment
  • 5.6. Italy
    • 5.6.1. Diagnosis
    • 5.6.2. Drug Treatment
  • 5.7. Spain
    • 5.7.1. Diagnosis
    • 5.7.2. Drug Treatment
  • 5.8. UK
    • 5.8.1. Diagnosis
    • 5.8.2. Drug Treatment
  • 5.9. Japan
    • 5.9.1. Diagnosis
    • 5.9.2. Drug Treatment
  • 5.10. Canada
    • 5.10.1. Diagnosis
    • 5.10.2. Drug Treatment
  • 5.11. China
    • 5.11.1. Diagnosis
    • 5.11.2. Drug Treatment
  • 5.12. India
    • 5.12.1. Diagnosis
    • 5.12.2. Drug Treatment

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Injectable Brands
    • 6.2.1. Betaseron
    • 6.2.2. Avonex
    • 6.2.3. Rebif
    • 6.2.4. Copaxone
    • 6.2.5. Tysabri
    • 6.2.6. Lemtrada
    • 6.2.7. Plegridy
  • 6.3. Product Profiles - Major Small Molecule Brands
    • 6.3.1. Gilenya
    • 6.3.2. Aubagio
    • 6.3.3. Tecfidera
  • 6.4. Other Disease-Modifying Therapies
    • 6.4.1. Overview

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Curative Therapies
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. The High Cost of MS Drugs
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Safety and Tolerability of Therapy
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Effective Treatments for Progressive MS
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Inconvenient Route of Administration and Frequent Dosing
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. MS Biomarkers for Early Diagnosis and Treatment Choice
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Zinbryta
    • 8.3.2. Ocrelizumab
    • 8.3.3. Ofatumumab
    • 8.3.4. Opicinumab
    • 8.3.5. Nerventra
    • 8.3.6. Masitinib
    • 8.3.7. Siponimod
    • 8.3.8. Ozanimod
    • 8.3.9. Ponesimod
  • 8.4. Late-Stage Therapeutic Vaccines
    • 8.4.1. NeuroVax
    • 8.4.2. Tcelna
  • 8.5. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Biogen
    • 9.3.2. Teva
    • 9.3.3. Merck Serono (EMD Serono)
    • 9.3.4. Sanofi (Genzyme)
    • 9.3.5. Bayer
    • 9.3.6. Novartis
    • 9.3.7. Roche

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Canada
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. China
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. India
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed MS Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Launch and Patent Expiry Dates
    • 11.4.4. General Pricing Assumptions
    • 11.4.5. Individual Drug Assumptions
    • 11.4.6. Generic Erosion
    • 11.4.7. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Director of Therapy Research and Analysis
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Common Presenting Symptoms of MS
  • Table 2: Factors That Can Affect Prognosis in MS
  • Table 3: Risk Factors and Comorbidities for MS
  • Table 4: Sources of MS Diagnosed Prevalence and Diagnosed Incidence Data Used in the Epidemiology Forecast
  • Table 5: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Table 6: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N (Row %), 2014
  • Table 7: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, by Sex, N (Row %), 2014
  • Table 8: 10MM, Diagnosed Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Table 9: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N (Row %), 2014
  • Table 10: 10MM, Diagnosed Incident Cases of MS, by Sex, N (Row %), 2014
  • Table 11: Revised 2010 McDonald Criteria for the Diagnosis of MS
  • Table 12: Treatment Guidelines for MS
  • Table 13: Top Three Disease-Modifying Therapies Prescribed for MS by Market
  • Table 14: Pharmacotherapy for Common MS Symptoms
  • Table 15: US - MS Diagnosis Metrics
  • Table 16: US - MS Treatment Metrics
  • Table 17: France - MS Diagnosis Metrics
  • Table 18: France - MS Treatment Metrics
  • Table 19: Germany - MS Diagnosis Metrics
  • Table 20: Germany - MS Treatment Metrics
  • Table 21: Italy - MS Diagnosis Metrics
  • Table 22: Italy - MS Treatment Metrics
  • Table 23: Spain - MS Diagnosis Metrics
  • Table 24: Spain - MS Treatment Metrics
  • Table 25: UK - MS Diagnosis Metrics
  • Table 26: UK - MS Treatment Metrics
  • Table 27: Japan - MS Diagnosis Metrics
  • Table 28: Japan - MS Treatment Metrics
  • Table 29: Canada - MS Diagnosis Metrics
  • Table 30: Canada - MS Treatment Metrics
  • Table 31: China - MS Diagnosis Metrics
  • Table 32: China - MS Treatment Metrics
  • Table 33: India - MS Diagnosis Metrics
  • Table 34: India - MS Treatment Metrics
  • Table 35: Leading Disease-Modifying Drugs for the Treatment of MS, 2015
  • Table 36: Product Profile - Betaseron
  • Table 37: Betaseron SWOT Analysis, 2015
  • Table 38: Global Sales Forecasts ($m) for Betaseron, 2014-2024
  • Table 39: Product Profile - Avonex
  • Table 40: Avonex SWOT Analysis, 2015
  • Table 41: Global Sales Forecasts ($m) for Avonex, 2014-2024
  • Table 42: Product Profile - Rebif
  • Table 43: Rebif SWOT Analysis, 2014
  • Table 44: Global Sales Forecasts ($m) for Rebif, 2014-2024
  • Table 45: Product Profile - Copaxone
  • Table 46: Copaxone SWOT Analysis, 2015
  • Table 47: Global Sales Forecasts ($m) for Copaxone, 2014-2024
  • Table 48: Product Profile - Tysabri
  • Table 49: Tysabri SWOT Analysis, 2015
  • Table 50: Global Sales Forecasts ($m) for Tysabri, 2014-2024
  • Table 51: Product Profile - Lemtrada
  • Table 52: Lemtrada SWOT Analysis, 2015
  • Table 53: Global Sales Forecasts ($m) for Lemtrada, 2014-2024
  • Table 54: Product Profile - Plegridy
  • Table 55: Clinical and MRI Endpoints at Year 1 from a Phase III Trial of Plegridy in MS
  • Table 56: Clinical and MRI Endpoints at Year 2 from a Phase III Trial of Plegridy in MS
  • Table 57: Adverse Events During Year 1 of a Phase III Trial of Plegridy in MS
  • Table 58: Plegridy SWOT Analysis, 2015
  • Table 59: Global Sales Forecasts ($m) for Plegridy, 2014-2024
  • Table 60: Product Profile - Gilenya
  • Table 61: Gilenya SWOT Analysis, 2015
  • Table 62: Global Sales Forecasts ($m) for Gilenya, 2014-2024
  • Table 63: Product Profile - Aubagio
  • Table 64: Aubagio SWOT Analysis, 2015
  • Table 65: Global Sales Forecasts ($m) for Aubagio, 2014-2024
  • Table 66: Product Profile - Tecfidera
  • Table 67: Tecfidera SWOT Analysis, 2015
  • Table 68: Global Sales Forecasts ($m) for Tecfidera, 2014-2024
  • Table 69: Summary of Alternative MS DMTs, 2014
  • Table 70: Unmet Need and Opportunity in MS
  • Table 71: Product Profile - Zinbryta High-Yield Process
  • Table 72: Adverse Events during Year 1 of a Phase III trial of Zinbryta in MS
  • Table 73: Zinbryta SWOT Analysis, 2015
  • Table 74: Global Sales Forecasts ($m) for Zinbryta, 2014-2024
  • Table 75: Product Profile - Ocrelizumab
  • Table 76: Ocrelizumab SWOT Analysis, 2015
  • Table 77: Global Sales Forecasts ($m) for ocrelizumab, 2014-2024
  • Table 78: Product Profile - Ofatumumab
  • Table 79: Ofatumumab SWOT Analysis, 2015
  • Table 80: Global Sales Forecasts ($m) for Ofatumumab, 2014-2024
  • Table 81: Product Profile - Opicinumab
  • Table 82: Opicinumab SWOT Analysis, 2015
  • Table 83: Product Profile - Nerventra
  • Table 84: Nerventra SWOT Analysis, 2015
  • Table 85: Global Sales Forecasts ($m) for Nerventra, 2014-2024
  • Table 86: Product Profile - Masitinib
  • Table 87: Masitinib SWOT Analysis, 2015
  • Table 88: Global Sales Forecasts ($m) for Masitinib, 2014-2024
  • Table 89: Product Profile - Siponimod
  • Table 90: Siponimod SWOT Analysis, 2015
  • Table 91: Global Sales Forecasts ($m) for siponimod, 2014-2024
  • Table 92: Product Profile - Ozanimod
  • Table 93: Ozanimod SWOT Analysis, 2015
  • Table 94: Global Sales Forecasts ($m) for Ozanimod, 2014-2024
  • Table 95: Product Profile - Ponesimod
  • Table 96: Efficacy Results for Ponesimod in a Phase IIb MS Trial
  • Table 97: Ponesimod SWOT Analysis, 2015
  • Table 98: Global Sales Forecasts ($m) for Ponesimod, 2014-2024
  • Table 99: Product Profile - NeuroVax
  • Table 100: NeuroVax SWOT Analysis, 2015
  • Table 101: Product Profile - Tcelna
  • Table 102: Tcelna SWOT Analysis, 2015
  • Table 103: Drugs in Development, 2015
  • Table 104: Key Companies in the MS Market, 2015
  • Table 105: Biogen's Multiple Sclerosis Portfolio Assessment, 2015
  • Table 106: Biogen SWOT Analysis, 2015
  • Table 107: Teva's MS Portfolio Assessment, 2015
  • Table 108: Teva SWOT Analysis, 2015
  • Table 109: Merck's Multiple Sclerosis Portfolio Assessment, 2015
  • Table 110: Merck SWOT Analysis, 2015
  • Table 111: Sanofi's Multiple Sclerosis Portfolio Assessment, 2015
  • Table 112: Sanofi SWOT Analysis, 2015
  • Table 113: Bayer's MS Portfolio Assessment, 2015
  • Table 114: Bayer SWOT Analysis, 2015
  • Table 115: Novartis' MS Portfolio Assessment, 2015
  • Table 116: Novartis SWOT Analysis, 2015
  • Table 117: Roche's Multiple Sclerosis Portfolio Assessment, 2015
  • Table 118: Roche SWOT Analysis, 2015
  • Table 119: Global Sales Forecast ($m) for MS, 2014-2024
  • Table 120: Global MS Market - Drivers and Barriers, 2014-2024
  • Table 121: Sales Forecast ($m) for MS in the United States, 2014-2024
  • Table 122: Key Events Impacting Sales for MS in the US, 2014-2024
  • Table 123: MS Market in the US - Drivers and Barriers, 2014-2024
  • Table 124: Sales Forecasts ($m) for MS in the 5EU, 2014-2024
  • Table 125: Key Events Impacting Sales for MS in the 5EU, 2014-2024
  • Table 126: MS Market in the 5EU - Drivers and Barriers, 2014-2024
  • Table 127: Sales Forecasts ($m) for MS in the Japan, 2014-2024
  • Table 128: Key Events Impacting Sales for MS in Japan, 2014-2024
  • Table 129: MS Market in Japan - Drivers and Barriers, 2014-2024
  • Table 130: Sales Forecasts ($m) for MS in the Canada, 2014-2024
  • Table 131: Key Events Impacting Sales for MS in Canada, 2014-2024
  • Table 132: MS Market in Canada - Drivers and Barriers, 2014-2024
  • Table 133: Sales Forecasts ($m) for MS in the China, 2014-2024
  • Table 134: Key Events Impacting Sales for MS in China, 2014-2024
  • Table 135: MS Market in China - Drivers and Barriers, 2014-2024
  • Table 136: Sales Forecasts ($m) for MS in the India, 2014-2024
  • Table 137: Key Events Impacting Sales for MS in India, 2014-2024
  • Table 138: MS Market in India - Drivers and Barriers, 2014-2024
  • Table 139: Key Launch Dates
  • Table 140: Key Patent Expiries
  • Table 141: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Accrual of Disability in the Four Subtypes of MS
  • Figure 2: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Figure 3: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N, 2014
  • Figure 4: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, by Sex, N, 2014
  • Figure 5: 10MM, Diagnosed Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Figure 6: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N, 2014
  • Figure 7: 10MM, Diagnosed Incident Cases of MS, by Sex, N, 2014
  • Figure 8: 10MM, MS Subtype Distributions, %*, 2014
  • Figure 9: Expanded Disability Status Scale (EDSS)
  • Figure 10: Algorithm for the Treatment of MS with Disease-Modifying Therapies
  • Figure 11: MS Therapeutics - Clinical Trials by Country, 2015
  • Figure 12: Multiple Sclerosis - Phase II-III Pipeline, 2015
  • Figure 13: Competitive Assessment of Late-Stage Pipeline Agents in MS, 2014-2024
  • Figure 14: Multiple Sclerosis - Phase II-III Therapeutic Vaccines, 2015
  • Figure 15: Company Portfolio Gap Analysis in MS, 2014-2024
  • Figure 16: Global Sales for MS by Region, 2014-2024
  • Figure 17: Global Sales for MS by Therapy Type, 2014-2024
  • Figure 18: Sales for MS in the United States by Therapy Type, 2014-2024
  • Figure 19: Sales for MS in the 5EU by Therapy Type, 2014-2024
  • Figure 20: Sales for MS in Japan by Therapy Type, 2014-2024
  • Figure 21: Sales for MS in Canada by Therapy Type, 2014-2024
  • Figure 22: Sales for MS in China by Therapy Type, 2014-2024
  • Figure 23: Sales for MS in India by Drug Class, 2014-2024
Back to Top